Fate Therapeutics, Inc.
NGM: FATELive Quote
📈 ZcoreAI Score
Our AI model analyzes Fate Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get FATE Z-Score →About Fate Therapeutics, Inc.
Healthcare
Biotechnology
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Fate Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -26.4% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -51.8%, which indicates that capital utilization is currently under pressure.
At a current price of $1.24, FATE currently sits at the 35th percentile of its 52-week range (Range: $0.87 - $1.94).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$144.17M
Trailing P/E
--
Forward P/E
-1.18
Beta (5Y)
2.24
52W High
$1.94
52W Low
$0.87
Avg Volume
1.60M
Day High
Day Low